At 25, Michael Walters had already endured unsuccessful lymphoma treatments in New Zealand. A Melbourne hospital quoted up to US$600,000 for CAR-T therapy. He paid less than half that in Shanghai and learned on August 18 that his cancer was in complete remission. CAR-T, or chimeric antigen receptor T-cell therapy, re-engineers a patient’s own immune […]
The post Cheaper CAR-T therapy drawing global cancer patients to China appeared first on Asia Times.
